Iberdomide

• Description :

  Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities[1][2].

• Product Name Alternative :

  CC-220

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Apoptosis; Ligands for E3 Ligase; Molecular Glues

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; PROTAC

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Iberdomide.html

• Purity :

  99.54

• Solubility :

  DMSO : 175 mg/mL (ultrasonic)

• Smiles :

  O=C([C@@H](N(CC1=C2C=CC=C1OCC3=CC=C(CN4CCOCC4)C=C3)C2=O)CC5)NC5=O

• Molecular Formula :

  C25H27N3O5

• Molecular Weight :

  449.50

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34 (4) :1197-1201.|[2]Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2 (4) :354-369.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  Cereblon

• CAS Number :

  [1323403-33-3]